Baird Capital portfolio company Azzur Group (“Azzur”) today announced the expansion of its ongoing business relationship with the life sciences company Moderna TX, Inc. (“Moderna”). Earlier this year, Moderna made headlines by producing one of the earliest vaccines approved in the fight against the COVID-19 pandemic.

Azzur and Moderna have worked together for more than six years in the Boston area, where Azzur has multiple Cleanrooms on Demand facilities. As part of the expanded relationship, Moderna will become the anchor client in Azzur’s newest facility in nearby Burlington, Mass, which will allow the company to expand its clinical manufacturing capacity.

“We are thrilled for the team at Azzur,” said Brett Tucker, Partner with Baird Capital’s private equity team. “This announcement comes at a critical time in the life sciences industry, and we are proud to be invested in a company that is helping to bring these advanced therapies to life.” 

Baird Capital announced its investment in Azzur in April 2021. To learn more about Azzur’s expanded partnership with Moderna, click here.